The combination of atezolizumab and bevacizumab has become the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). However, no studies have reported on specific intestinal microbiota associated with the efficacy of atezolizumab and bevacizumab. In this study, we analyzed fecal samples collected before treatment to investigate the relationship between the intestinal microbiome and the efficacy of atezolizumab and bevacizumab. A total of 37 patients with advanced HCC who were treated with atezolizumab and bevacizumab were enrolled. Fecal samples were collected from the patients, and they were divided into responder (n= 28) and non-responder (n= 9) groups. We compared the intestinal microbiota of the two groups and analyzed the intestinal bacteria associated with prognosis using QIIME2. The alpha and beta diversities were not significantly different between both groups, and the proportion of microbiota was similar. The relative abundance ofBacteroides stercorisandParabacteroides merdaewas higher in the responder group than in the non-responder group. When the prognosis was analyzed by the presence or absence of those bacteria, patients without both had a significantly poorer prognosis. Differences in intestinal microbiome are involved in the therapeutic effect of atezolizumab and bevacizumab.
阿替利珠单抗联合贝伐珠单抗已成为不可切除肝细胞癌患者的一线治疗方案。然而，目前尚无研究报道与阿替利珠单抗和贝伐珠单抗疗效相关的特定肠道菌群。本研究通过分析治疗前收集的粪便样本，探讨肠道微生物组与阿替利珠单抗和贝伐珠单抗疗效之间的关系。共纳入37例接受阿替利珠单抗联合贝伐珠单抗治疗的晚期肝细胞癌患者。收集患者粪便样本，并将其分为应答组（28例）和无应答组（9例）。我们比较了两组患者的肠道菌群，并使用QIIME2分析了与预后相关的肠道细菌。两组间的α和β多样性无显著差异，微生物组成比例相似。应答组中类固醇杆菌和粪副拟杆菌的相对丰度高于无应答组。根据这些细菌的存在与否进行预后分析时，两种细菌均缺失的患者预后显著较差。肠道微生物组的差异与阿替利珠单抗和贝伐珠单抗的治疗效果相关。
肿瘤(癌症)患者之家